Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Last 12 months price action with 12-month analyst target path
As of May 8, 2026, Universal Technical Institute, Inc. (UTI) has a Wall Street consensus price target of $49.00, based on estimates from 11 covering analysts. With the stock currently trading at $35.54, this represents a potential upside of +37.9%. The company has a market capitalization of $1.96B.
Analyst price targets range from a low of $49.00 to a high of $49.00, representing a 0% spread in expectations. The median target of $49.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 2 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, UTI trades at a trailing P/E of 31.5x and forward P/E of 44.5x. The forward PEG ratio of 0.53 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +4.3% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationSide-by-side business, growth, and profitability comparison vs Walmart Inc..
Start ComparisonQuick answers to the most common questions about buying UTI stock.
The consensus Wall Street price target for UTI is $49, representing 37.9% upside from the current price of $35.54. With 11 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
UTI has a consensus rating of "Buy" based on 11 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $49 implies 37.9% upside from current levels.
At a forward P/E of 44.5029x, UTI trades at a premium valuation. The consensus price target of $49 (37.9% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $49 for UTI, while the most conservative target is $49. The consensus of $49 represents the median expectation. These targets typically reflect 12-month expectations.
UTI is moderately covered, with 11 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 1 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month UTI stock forecast based on 11 Wall Street analysts shows a consensus price target of $49, with estimates ranging from $49 (bear case) to $49 (bull case). The median consensus rating is "Buy".
UTI trades at a forward P/E ratio of 44.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 31.5x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on UTI, with a "Buy" consensus rating and $49 price target (37.9% upside). 8 of 11 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
UTI analyst price targets range from $49 to $49, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $49 consensus represents the middle ground.